Back to catalogue
№ 152 39 filings · 2021-04-28 → 2026-05-06

RENISHAW PLC

RSW
Industrial Goods and Services Market cap £3.9bn Overall fit 580 /1000

Strong fit on AI-receiver semi-capex exposure and operating leverage with closing margin gap, and excellent downside protection from net-cash balance sheet, but at ~28x forward P/E the valuation already prices in much of the cyclical and margin recovery rather than offering a margin of safety.

Fair value range 4,000p–4,800p Mid case · £3.2bn
Absolute upside -19% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Clean detailed disclosures and audited financials
  • Two independent valuation methods converge on similar fair-value range
  • Recent guidance upgrade and order-book expansion corroborate the operating-leverage and cyclical-recovery thesis
Limits the call
  • Reaching the 20% adjusted operating margin target is the single largest swing factor on multiple
  • Semiconductor capex visibility beyond 12 months is inherently weak
Methodology

Forward P/E 22-26x cross-checked against target-based DCF

In one line · bull case

High-quality, net-cash precision-metrology business with genuine semi-capex AI-receiver exposure and meaningful operating leverage as the cycle recovers and margins close in on the 20% target.

In one line · biggest risk

A reversal of the current semiconductor and electronics capex upswing would unwind the order book, stall the margin recovery and re-rate a stock already trading at ~28x forward earnings.

Drivers
AI beneficiary 60 /100
Position encoders ship into semiconductor wafer-handling and electronics manufacturing equipment with explicit demand pull from the semi-capex cycle.
Operating leverage 70 /100
High fixed-cost manufacturing-tech business with completed £23m cost programme, spare capacity from Miskin expansion, and 4.4%pt organic margin uplift quantified in H1 FY26.
Earnings vs expectations 55 /100
Mixed record over the period: trading-statement guidance cuts in 2023-2025 but recent FY26 upgrade is positive.
Growth momentum 70 /100
Accelerating: +13.5% constant-FX 9M FY26 with broad-based growth across all three segments and an expanded order book.
Moat 70 /100
Patented sensor/encoder IP, deep customer integration, in-house precision manufacturing; some erosion risk from low-price competition in APAC.
Earnings quality 75 /100
Clean cash-generative earnings, modest adjusted-vs-statutory gap from restructuring and a legacy tax provision, 68% H1 FY26 cash conversion below 70% target.
Management quality 60 /100
Founder-led with progressive dividend, but ongoing CFO/Chair/NED searches and 22-30% protest votes against founder re-elections signal governance transition.
Cyclicality 65 /100
Deeply cyclical exposure to semiconductor, machine tools, aerospace and consumer-electronics capex.
Leverage 10 /100
£240.9m net cash with ~£2m borrowings – fortress balance sheet.

RENISHAW PLC (RSW) – Investment Research Note

Executive summary

Renishaw designs and manufactures precision measurement and process-control systems – CMM probes, position encoders, machine-tool calibration, and metal additive-manufacturing machines – with most R&D and production in the UK, Ireland and India. After two flat-ish years (FY24-25, ~£691-713m revenue, adjusted PBT compressed to ~£123-127m by currency, semiconductor downcycle and pay inflation), the business is now visibly inflecting: H1 FY26 delivered +11.5% constant-FX growth, the order book has expanded substantially, and management upgraded FY26 guidance in April 2026 to revenue of £775-805m and adjusted PBT of £145-165m. The single most important valuation point today is that the cyclical and structural drivers (semiconductor capex, defence, additive manufacturing) are converging just as a recently completed £20m annual cost programme and the Miskin capacity expansion give Renishaw genuine operating leverage – but the shares already trade at a high-twenties forward P/E that prices in much of the recovery.

Fair value estimate

  • Methodology: forward P/E cross-checked against an implied 5-year through-cycle DCF, anchored on the company's own targets (high-single-digit revenue growth, 20%+ adjusted operating margin).
  • Key assumptions:
    • FY26 adjusted PBT lands mid-guidance at £155m (£122m adjusted net income at 21% tax, ~168p EPS).
    • FY27 revenue ~£860-900m (8-10% growth as semi/defence cycle and emerging products continue), adjusted operating margin recovering to 17-18%, adjusted PBT ~£165-180m.
    • Fair multiple range of 22-26x forward P/E – consistent with quality industrial-technology peers (Spectris, Hexagon) given Renishaw's net-cash balance sheet, R&D intensity, and semi-cap exposure, but capped vs. a Keyence-style ~30x because Renishaw still has cyclicality and a lower through-cycle margin.
  • Fair value range: roughly 4,000p – 4,800p per share, equivalent to £2,910m – £3,495m market cap. Mid-point ~4,400p / £3,200m.
  • vs. current market cap £3,445.8m (~4,733p): implied downside of ~7% to mid-point, range of roughly -15% to +1%. Fair to slightly overvalued; the shares are pricing in a clean cycle recovery.

Sector context

  • Sector classification confirmed: Industrial Goods and Services (ICB), within capital-equipment / precision instruments. Cyclical exposure to semiconductor capex, machine-tool builders, aerospace/defence and consumer-electronics manufacturing.
  • Renishaw's quality (net-cash balance sheet, mid-50s gross margin, deep IP) is above sector average; growth has been broadly in line through-cycle (5-yr CAGR of ~7.8% per H1 FY26 disclosure), but margins (15-17% adjusted operating) sit below best-in-class peers like Keyence (~50%) and below the company's own 20% target.
  • Closest listed peers: Spectris (LSE: SXS) – UK precision instrumentation; Hexagon (STO: HEXA-B) – metrology and sensors at larger scale; Keyence (TYO: 6861) – best-in-class precision sensors with semi exposure.

Investment thesis (3 bullets)

  • Genuine semiconductor-capex picks-and-shovels exposure: Position Measurement (encoders) grew 21.6% constant-FX over 9M FY26, with "very strong sales growth for open optical and magnetic encoders" and "order intake … accelerated in the third quarter, notably from the semiconductor and electronics manufacturing equipment sector" 2026-05-06 trading statement. These encoders go inside the wafer-handling and inspection equipment that underpins AI chip capacity build-out – this is direct demand pull, not a press-release AI mention.
  • Operating leverage is starting to deliver: H1 FY26 disclosed a +4.4%pt organic margin uplift "from a combination of fixed cost reduction, productivity initiatives and operating leverage", with ~£23m annualised payroll savings now flowing and headcount down 372 since June 2025 2026-02-11 H1 results. With the Miskin expansion (~50% extra UK manufacturing floorspace) operational, incremental revenue can absorb existing fixed costs.
  • Fortress balance sheet enables through-cycle compounding: £240.9m cash and deposits at 31 Dec 2025 vs. £2.4m borrowings; ROIC up to 13.2%; progressive dividend (16.8p interim, 78.1p total FY25) 2026-02-11 H1; 2025-09-18 FY25 final. Net cash plus deep IP means Renishaw can keep investing in R&D (£106-120m gross engineering spend) through downturns and won't dilute holders.

Key risks (3 bullets)

  • Cyclicality and semi-capex reversal: encoder demand collapsed in FY24-25 when the semi cycle turned (PM adjusted operating profit fell 9% in H1 FY26 despite the recovery), and management acknowledges "we operate in cyclical markets" 2026-02-11 H1 results. A faster-than-expected ASML-type capex pause would unwind the order book and the upgraded guidance.
  • Margin recovery may stall short of the 20% target: adjusted operating margin of 15.7% in H1 FY26 vs. 20% target – currency headwinds and product/customer mix are recurring drags, and the China low-price competition risk is now flagged as a principal risk 2026-02-11 H1; 2025-09-18 FY25. The path from 15.7% to 20% requires both volume growth and continued mix improvement.
  • Governance / succession overhang: CFO Allen Roberts retired Dec 2025 (interim in place), an independent Non-executive Chair search is still ongoing, and 50.25% of share capital is now held by founder-family holding company "Deltam" with deadlock-resolution rules that some shareholders may dislike 2025-11-26 AGM result; 2026-02-11 H1. A failed 2021 formal sale process and 22-30% protest votes against founder re-elections at recent AGMs underline the unresolved tension.

Operating leverage

Renishaw is structurally a high-fixed-cost business: gross engineering spend is essentially fixed at ~£106-120m p.a., distribution costs (£140m+) are largely fixed sales-coverage costs, and admin is fixed central overhead. Gross margin excluding engineering was 58.8% in H1 FY26 (61.5% prior year), so the incremental contribution margin on each pound of extra revenue – once capacity is in place – is well above 50%. Management explicitly quantified the leverage in H1 FY26: "2.0%pt of operating leverage arising from our strong constant currency revenue growth", on top of 2.4%pt from cost reduction 2026-02-11 H1. The Miskin Wales expansion has just added ~50% manufacturing floorspace, and headcount has been cut by ~370 since June 2025 – so the business now has both physical and labour capacity to absorb growth without proportional cost increases. If H2 FY26 revenue runs ~£385m (consistent with guidance), and pricing/mix hold, the contribution from each additional £100m of revenue above plan should drop ~£40-50m to operating profit – i.e. a 10-15% revenue beat versus the £790m midpoint could plausibly add 25-40% to adjusted operating profit, materially closing the gap to the 20% margin target 2025-09-18 FY25 final; 2026-02-11 H1. Real upside optionality for AI-driven semi capex.

Value-trap signals

None identified. Revenue is growing again, order book is expanding, dividend has been maintained/grown (FY25 +2.5%), there are no going-concern issues, balance sheet is net cash, no customer concentration above 10%, and no aggressive accounting flagged in audit reports. The semi cyclicality is a feature, not a value trap. The only mild caveats are: (i) the founder-family controlled structure now consolidated in Deltam; (ii) the historical/non-recurring tax provisions of £9.2m + £4.9m interest in FY25 (legacy structures); and (iii) the H1 FY26 statutory profit being depressed by £18m of one-offs.

Earnings vs. expectations

The track record across the period is mixed but trending positive recently. FY22 was a record beat (revenue £671m vs. low expectations after the formal sale process). FY23 and FY24 saw a series of trading-statement-driven mid-year guidance cuts or in-line deliveries as semi capex weakened. FY25 was guided down at H1 (Feb 2025 range £695-735m revenue / £105-135m adjusted PBT) and the company landed at £713m / £127m (i.e. near midpoint of both ranges and slightly above the May 2025 narrowed range of £700-720m / £109-127m). FY26 has been an upward trend: initial February guidance £740-780m / £132-157m was raised in April 2026 to £775-805m / £145-165m. Pattern: management is conservative at the start of cycles and beat-and-raise as semi recovers; recent direction is positive but the 2022-2024 history is closer to "in-line to mild miss" than consistent beats.

Conviction

Conviction: 4 (high).

Anchors: (i) the financial disclosure is detailed, audited, internally consistent and the balance sheet is unambiguous – cash, debt and pension positions are all clearly laid out; (ii) two independent valuation methods (forward P/E vs. peers, and target-based DCF) converge on a similar £2.9-3.5bn fair-value range; (iii) the operating-leverage and cyclical-recovery thesis is corroborated by the upgraded FY26 guidance and order-book commentary, not just by hopes.

Limiters: (i) the right multiple for the business depends heavily on whether the 20% adjusted operating margin target is reached or stalls in the 16-18% range – a 4%pt difference moves fair value materially; (ii) semiconductor capex visibility beyond 12 months is genuinely poor, so the FY27 growth assumption is the largest single judgement call.

Driver scoring rationale (brief)

  • ai_beneficiary 60 – Position encoders ship directly into semiconductor wafer-handling and electronics manufacturing equipment, with the company explicitly flagging "rising demand from existing accounts" in the semi sector. Not a pure AI play (no software/data moat), but a genuine semi-capex picks-and-shovels exposure with verified revenue acceleration.
  • operating_leverage 70 – High fixed-cost manufacturing-tech business with completed cost reductions, spare capacity from Miskin, and management quantifying 4.4%pt organic margin uplift in H1 FY26. Clear gap (15.7% vs. 20% target) means real upside from volume.
  • earnings_surprise_trend 55 – Recent upgrade is positive, but 2023-2025 history is closer to in-line/cuts than consistent beats.
  • cyclicality 65 – Deeply cyclical (semiconductor, machine tools, aerospace, consumer electronics). Diversified across multiple cyclical end-markets, but not defensive.
  • moat 70 – Patented sensor/encoder IP, deep customer integration, market-leadership in precision metrology, in-house manufacturing. Threatened modestly by low-price competition (China) and emerging substitute technologies.
  • leverage 10 – £241m net cash, ~£2m borrowings. Fortress balance sheet.
  • earnings_quality 75 – Clean cash-generative earnings, 68% H1 FY26 cash conversion (below 100% target H1 FY25 but in line with stepped-up capex/working capital), some adjusted-vs-statutory gap from restructuring and a legacy tax provision.
  • management_quality 60 – Founder-led with long-term focus and progressive dividend, but CFO retirement, interim Chair, search for new Chair and independent NED, plus 25-30% protest votes against founder re-elections, all suggest a governance/succession transition. Failed 2021 FSP also indicates strategic options were tested.
  • growth_momentum 70 – Accelerating: 13.5% constant-FX 9M FY26, upgraded guidance, growing order book, with broad-based growth across all three segments.

Overall score 580

Renishaw fits two of the investor's three pillars well (real AI-receiver exposure via semi capex; significant operating leverage with spare capacity and a closing margin gap to target) and offers excellent downside protection via the net-cash balance sheet. The valuation discipline pillar pulls the score down: at ~28x forward P/E and roughly fair to slightly overvalued on a mid-cycle basis, you are paying for the recovery rather than getting it free. A high-quality name to own at a fair-to-slightly-stretched price, not a bargain.

Filings consulted · 37

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-06Trading Statement2026-05-06_9553606_trading-statement.md0.85
  2. 2026-04-20Trading Statement2026-04-20_9526927_trading-statement.md0.85
  3. 2026-02-11Half Year Financial Report2026-02-11_9424652_half-year-financial-report.md0.90
  4. 2026-01-29Notice OF Half Year Results2026-01-29_9394037_notice-of-half-year-results.md0.90
  5. 2025-11-26Result OF Agm2025-11-26_9259102_result-of-agm.md0.30
  6. 2025-10-23Trading Statement2025-10-23_9188562_trading-statement.md0.72
  7. 2025-09-18Final Results2025-09-18_9115235_final-results.md0.85
  8. 2025-08-21Board Change And Trading Update2025-08-21_9066729_board-change-and-trading-update.md0.72
  9. 2025-06-17Capital Markets Day2025-06-17_8932414_capital-markets-day.md0.81
  10. 2025-05-08Trading Statement2025-05-08_8866470_trading-statement.md0.55
  11. 2025-02-13Half Year Report2025-02-13_8734514_half-year-report.md0.58
  12. 2024-11-27Result OF Agm2024-11-27_8576424_result-of-agm.md0.20
  13. 2024-10-24Trading Statement2024-10-24_8505246_trading-statement.md0.55
  14. 2024-09-12Final Results2024-09-12_8412429_final-results.md0.65
  15. 2024-05-08Trading Statement2024-05-08_8180880_trading-statement.md0.38
  16. 2024-02-06Half Year Report2024-02-06_8022988_half-year-report.md0.41
  17. 2024-01-23Notice OF Half Year Results2024-01-23_8002119_notice-of-half-year-results.md0.41
  18. 2023-11-29Result OF Agm2023-11-29_7910744_result-of-agm.md0.14
  19. 2023-10-26Trading Statement2023-10-26_7839870_trading-statement.md0.38
  20. 2023-10-13Notice OF Agm2023-10-13_7814110_notice-of-agm.md0.14
  21. 2023-09-19Final Results2023-09-19_7763278_final-results.md0.45
  22. 2023-04-28Trading Statement2023-04-28_7388_trading-statement.md0.21
  23. 2023-02-02Half Year Report2023-02-02_7352617_half-year-report.md0.23
  24. 2023-01-24Notice OF Half Year Results2023-01-24_7155564_notice-of-half-year-results.md0.23
  25. 2022-11-30Result OF Agm2022-11-30_7264520_result-of-agm.md0.07
  26. 2022-10-31Notice OF Agm2022-10-31_7208162_notice-of-agm.md0.07
  27. 2022-10-27Trading Statement2022-10-27_7160800_trading-statement.md0.21
  28. 2022-09-15Final Results2022-09-15_7316251_final-results.md0.25
  29. 2022-05-10Trading Statement2022-05-10_7240798_trading-statement.md0.21
  30. 2022-02-03Half Year Report2022-02-03_6707765_half-year-report.md0.23
  31. 2022-01-17Notice OF Half Year Results2022-01-17_6858133_notice-of-half-year-results.md0.23
  32. 2021-11-24Result OF Agm2021-11-24_6591043_result-of-agm.md0.07
  33. 2021-10-21Trading Statement2021-10-21_6522486_trading-statement.md0.21
  34. 2021-10-21Final Results Replacement2021-10-21_6523633_final-results-replacement.md0.25
  35. 2021-10-21Final Results2021-10-21_6522537_final-results.md0.25
  36. 2021-09-27Final Results Revised Date And Trading Update2021-09-27_6591719_final-results-revised-date-and-trading-update.md0.25
  37. 2021-04-28Trading Statement2021-04-28_6628621_trading-statement.md0.09

This research note was authored by a large language model after reading 39 regulatory filings published between 2021-04-28 and 2026-05-06. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.